Class IITerminatedD-0855-2022
Drug recall · May 18, 2022
MVASI (bevacizumab-awwb) recall
Why: Defective container: loose crimp defect, potential loss of container integrity.
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
MVASI (bevacizumab-awwb), Injection, For Intravenous Infusion After Dilution, 100 mg/4 ml, Single dose vial, Rx only, Manufactured by Amgen Inc. Thousand Oaks, CA 91320-1799, NDC 55513-0206-01
- Lots / codes
Lots: 1142258, 1143196, Exp. 09/24
- Quantity
- 15,823
- Company
- Amgen, Inc., Thousand Oaks, CA
- Distribution
- Nationwide in the USA, Egypt and Lithuania.
- Initiated
- May 2, 2022 · Voluntary: Firm initiated
- Classified
- May 9, 2022
- Reported
- May 18, 2022
- Ended
- December 2, 2022
- How notified
- Letter
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.